Bone Biologics Corp. (BBLGW)

Overview

Bone Biologics Corporation is an innovative medical device company dedicated to transforming the field of bone regeneration with a particular focus on spinal fusion procedures. With its foundation in 2004 and headquartered in Burlington, Massachusetts, the company has emerged as a leader in developing advanced solutions aimed at fostering bone growth and healing. Utilizing the recombinant human protein, Bone Biologics is at the forefront of using biotechnology to address some of the most challenging conditions in skeletal and orthopedic health. Through strategic partnerships, such as with the UCLA Technology Development Group, Bone Biologics is advancing the applications of its ground-breaking technologies in spinal fusion and beyond, aiming to deliver superior outcomes across a range of surgical specialties including spinal, orthopedic, neurosurgery, and more.

Products and Services

• NELL-1/DBM

  An osteopromotive recombinant protein developed by Bone Biologics, NELL-1/DBM stands as the cornerstone of the company's product offerings. It is designed to provide targeted, specific control over bone regeneration, making it an invaluable tool in the treatment of spinal degeneration and other bone-related conditions.

• NELL-1/DBM Fusion Device

  Specifically tailored for spinal fusion procedures, the NELL-1/DBM Fusion Device caters to skeletally mature patients suffering from degenerative disc disease at one level from L2-S1. This device represents a significant advance in spinal surgery, offering the potential for improved outcomes through enhanced bone regeneration capabilities.

The company's platform technology not only emphasizes enhanced surgical outcomes but also broadens its potential applications across various medical and surgical specialties. These include general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine, showcasing the versatility and breadth of Bone Biologics' innovative approaches to bone regeneration.